Zoetis Inc Class A Common Stoc (ZTS) 51.26 $ZTS Blog

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Zoetis Inc Class A Common Stoc (ZTS) 51.26 $ZTS

Blog Coverage Valeant Pharma Appoints New CEO
ACCESSWIRE - Tue Aug 23, 8:15AM CDT
LONDON, UK / ACCESSWIRE / August 23, 2016 / Active Wall St. blog coverage looks at the headlines from Valeant Pharmaceuticals International, Inc. (NYSE: VRX) and Zoetis Inc. (NYSE: ZTS). Zoetis announced on August 21, 2016, that it had appointed Glenn David as its Executive Vice President and Chief Financial Officer (CFO). The announcement came in the wake of the resignation of Executive Vice President and CFO Paul S. Herendeen on August 18, 2016. On August, 22, 2016, Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced the appointment of Paul S. Herendeen to take on the role of CFO from Robert L. Rosiello. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
AGN: 235.96 (-1.80), ZTS: 51.26 (+0.15), VRX: 28.76 (-0.36), TROW: 69.27 (+0.52), VRX.TO: 37.34 (-0.75)

Eli Lilly, AstraZeneca Alzheimer's Drug Gets FDA Fast Track
Arpita Dutt - Zacks Investment Research - Tue Aug 23, 7:59AM CDT
Eli Lilly (LLY) and AstraZeneca's (AZN) Alzheimer's disease treatment is currently in phase III studies.
ZTS: 51.26 (+0.15), AZN: 33.31 (+0.71), LLY: 76.85 (-0.38)

Veterinary Vaccines Market is Expected to Rise to US$11,403.6 mn by 2024; Rising Expenditure on Animal Healthcare by Pet Owners and Livestock Farmers to Drive Market Globally, Reports TMR
PR Newswire Europe - Tue Aug 23, 6:31AM CDT
ALBANY, New York, August 23, 2016 /PRNewswire/ --
ZTS: 51.26 (+0.15), MRK: 62.98 (+0.08)

Zacks.com featured highlights: Macy's, Discovery Communications, Zoetis, Boston Scientific and Priceline Group
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 8:30AM CDT
Zacks.com featured highlights: Macy's, Discovery Communications, Zoetis, Boston Scientific and Priceline Group
BSX: 24.26 (-0.07), ZTS: 51.26 (+0.15), DISCK: 25.08 (+0.13), M: 36.64 (+0.30), PCLN: 1,422.85 (+4.26)

Zoetis Announces Appointment of Glenn David as Executive Vice President and Chief Financial Officer
BusinessWire - Sun Aug 21, 8:13PM CDT
Zoetis Inc. (NYSE:ZTS) today announced that Glenn David, Senior Vice President of Finance Operations, has been named Executive Vice President and Chief Financial Officer (CFO), and will assume responsibility for the oversight of the company's financial management, planning and global operations, effective immediately. As CFO, David will report directly to Chief Executive Officer Juan Ramon Alaix and become part of the Zoetis Executive Team. David will succeed Executive Vice President and Chief Financial Officer Paul Herendeen, who has resigned effective August 18, 2016, to accept the position of CFO at another public company.
ZTS: 51.26 (+0.15)

Top Research Reports for August 19, 2016
Sheraz Mian - Zacks Investment Research - Fri Aug 19, 10:44AM CDT
Top Research Reports for August 19, 2016
ZTS: 51.26 (+0.15), AVB: 175.46 (-0.35), LOW: 76.96 (+0.52), TEVA: 51.22 (+0.32), CMCSA: 66.16 (+0.27), VZ: 52.88 (+0.32)

5 Top ROE Stocks to Play in an Aging Bull Market
Supriyo Bose - Zacks Investment Research - Fri Aug 19, 7:05AM CDT
As investors scout for cherry pickings in an aging bull market, they are often on the lookout for "cash cow" stocks that would enable them to milk more cash or profits.
ZTS: 51.26 (+0.15), BSX: 24.26 (-0.07), DISCK: 25.08 (+0.13), M: 36.64 (+0.30), PCLN: 1,422.85 (+4.26)

Zoetis to Participate in the Morgan Stanley Global Healthcare Conference
BusinessWire - Thu Aug 11, 7:30AM CDT
Zoetis Inc.(NYSE:ZTS) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 14, 2016, in New York, N.Y. Juan Ramon Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 10:30 a.m. EDT.
ZTS: 51.26 (+0.15), MS: 31.89 (-0.02)

Zoetis Acquires Scandinavian Micro Biodevices to Extend Its Pipeline in Diagnostics for Veterinary Use
BusinessWire - Mon Aug 08, 7:00AM CDT
--Adds to diagnostics portfolio with specialty test instruments and cartridges
ZTS: 51.26 (+0.15)

Zacks.com featured highlights: Macy's, General Mills, Zoetis, Boston Scientific and Citrix Systems
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:30AM CDT
Zacks.com featured highlights: Macy's, General Mills, Zoetis, Boston Scientific and Citrix Systems
BSX: 24.26 (-0.07), ZTS: 51.26 (+0.15), M: 36.64 (+0.30), GIS: 70.94 (+0.83), CTXS: 86.98 (-0.30)

Zoetis (ZTS) Beats on Q2 Earnings & Revenues, Lifts Outlook
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 9:52AM CDT
Zoetis (ZTS) reported better-than-expected second-quarter 2016 earnings of 49 cents per share.
ZTS: 51.26 (+0.15), FCSC: 0.89 (-0.01), ANIP: 59.86 (-1.56), ANIK: 47.89 (-0.05)

Prothena (PRTA) Reports Wider-than-Anticipated Loss in Q2
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 9:45AM CDT
Prothena (PRTA) reported a wider-than-expected loss of $1.18 per share in the second quarter of 2016.
ZTS: 51.26 (+0.15), ANIP: 59.86 (-1.56), PRTA: 52.19 (-0.02)

Zoetis (ZTS) Tops Q2 Earnings, Revenue Estimates
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 8:19AM CDT
Zoetis (ZTS) beat both top- and bottom-line estimates in the second quarter of 2016.
ZTS: 51.26 (+0.15)

5 Top ROE Stocks to Buy as Earnings Growth Remains Elusive
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 7:57AM CDT
A high ROE ensures that the company is reinvesting its cash at a high rate of return.
ZTS: 51.26 (+0.15), BSX: 24.26 (-0.07), M: 36.64 (+0.30), GIS: 70.94 (+0.83), CTXS: 86.98 (-0.30)

Zoetis Reports Second Quarter 2016 Results
BusinessWire - Wed Aug 03, 6:00AM CDT
--Zoetis Reports Adjusted Net Income of $246 Million, or Adjusted Diluted EPS of $0.49, for Second Quarter 2016
ZTS: 51.26 (+0.15)

Drug Stocks to Watch for Earnings on Aug 3: ZTS, EXEL & More
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 9:30AM CDT
Can drug stocks Zoetis, Conatus and others pull a surprise when they report their Q2 results on Aug 3?
ZTS: 51.26 (+0.15), JNJ: 119.32 (+0.24), GILD: 76.89 (-0.53), GERN: 2.75 (+0.02), CNAT: 1.84 (-0.02), AERI: 19.60 (+0.39), EXEL: 11.54 (+0.19)

Keryx (KERX) Stock Down on Wider Q2 Loss, Supply Issues
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 8:17AM CDT
Keryx (KERX) announced disruption in the supply of Auryxia tablets along with disappointing second-quarter results.
ZTS: 51.26 (+0.15), INVA: 11.09 (+0.02), ANIP: 59.86 (-1.56), KERX: 4.15 (+0.02)

Sanofi (SNY) Posts In-Line Q2 Earnings, Revenues Down Y/Y
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 4:19PM CDT
Sanofi (SNY) reported second-quarter 2016 business earnings of 74 cents per American Depositary Share, in line with the Zacks Consensus Estimate.
ZTS: 51.26 (+0.15), INVA: 11.09 (+0.02), ANIP: 59.86 (-1.56), SNY: 39.18 (+0.77)

Zoetis (ZTS): Stock to Beat Earnings Estimates in Q2 Again
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 11:01AM CDT
Zoetis (ZTS), which is set to report second-quarter 2016 results on Aug 3, had delivered a positive earnings surprise of 17.07% last quarter.
ZTS: 51.26 (+0.15), ABT: 42.09 (-0.21), ICPT: 150.74 (+3.92), EXEL: 11.54 (+0.19)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
A Faded Sign Is a Quiet Leak in Storefront Demand Today

Updated Category News Views 95

Sunlight does not care what the marketing budget said. A storefront can have a decent product, a clean interior and a capable crew, then lose the first impression before anyone reaches the door because its sign looks tired. That is the plainspoken point behind FASTSIGNS' latest guidance on outdoor sign lifespan. This is not glamorous stuff, but it is operationally...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 25

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
Abacus Global Faces Scrutiny Over Accounting Practices

Updated Category News Views 128

Storm Clouds Gather over Abacus Global Management If it ain't one thing, it's another—at least that's what folks holding the bag with Abacus Global (ABX) are thinking right now. News of a pending investigation has dropped like a lead balloon, and the air is thick with scrutiny over their financial dealings. We're jawing about related-party transactions now under the...

Continue Reading
Max y Noelia Explore Trade at 9th CIIE in Shanghai

Updated Category News Views 60

Influencers at the Heart of Global Trade Exploration Makin' their debut on the big stage of the 9th China International Import Expo (CIIE), Mexican influencers Max y Noelia found themselves caught in a whirlwind of trade and cultural exchanges over in Shanghai. These digital mavens aren't just snapping selfies. Nope, they're capturing the very essence of international...

Continue Reading
Finzly Welcomes Paul Finch to Drive BankOS Growth

Updated Category News Views 20

Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...

Continue Reading
Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 27

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 186

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 114

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 84

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionary Prostate Treatment Program Launches in Dallas

Updated Category News Views 191

Transforming Prostate Care with the TULSA Program The landscape of prostate treatment is evolving, thanks to the groundbreaking advancements brought forth by Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) and its launch of the TULSA program in collaboration with Texas Prostate and Dallas Medical Center. This pioneering initiative aims to cater to the rising need for...

Continue Reading
Addex Expands Share Capital for Future Financial Flexibility

Updated Category News Views 254

Recent Developments at Addex Therapeutics Ad Hoc Announcement Addex Therapeutics, a clinical-stage biopharmaceutical firm, has made a significant move by issuing 34,300,000 new registered shares. These shares, issued by Addex Pharma S.A, a wholly-owned subsidiary, allow the company to strategically increase its issued share capital to CHF 2,186,544.96. This adjustment...

Continue Reading
Jasper Therapeutics Receives Major Boost from Oppenheimer's $80 Target

Updated Category News Views 130

Oppenheimer Affirms Positive Outlook for Jasper Therapeutics Jasper Therapeutics (NASDAQ:JSPR) has recently captured the attention of investors, particularly following Oppenheimer's announcement of its continued support with an Outperform rating and a notable price target set at $80. The positive sentiment originates from the recent findings of a Phase 1b/2a clinical...

Continue Reading
Taylor Morrison Launches New Resort Community Near Jacksonville

Updated Category News Views 286

Taylor Morrison Launches New Resort Community Near Jacksonville In an exciting development for homebuyers, Taylor Morrison, recognized as one of America’s Most Trusted® Home Builders, has officially broken ground on its first resort lifestyle community in the Jacksonville area. This ambitious project, named Esplanade at St. Marys, spans an impressive 1,250 acres and is...

Continue Reading
Middlefield Canadian Income PCC Report: NAV Insights

Updated Category News Views 123

Understanding Middlefield Canadian Income PCC's Financial Position Middlefield Canadian Income PCC is a notable player in the investment landscape, focusing on generating sustainable income from a diversified portfolio. Understanding its net asset value (NAV) is crucial for investors looking to gauge the company's financial stability and growth potential. Current Net...

Continue Reading